(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -10.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Biontech Se's revenue in 2024 is $4,151,086,956.On average, 5 Wall Street analysts forecast BNTX's revenue for 2024 to be $691,943,304,624, with the lowest BNTX revenue forecast at $510,040,326,717, and the highest BNTX revenue forecast at $782,383,920,973. On average, 5 Wall Street analysts forecast BNTX's revenue for 2025 to be $670,392,753,569, with the lowest BNTX revenue forecast at $388,579,354,659, and the highest BNTX revenue forecast at $951,746,866,359.
In 2026, BNTX is forecast to generate $709,887,318,553 in revenue, with the lowest revenue forecast at $449,215,106,982 and the highest revenue forecast at $1,093,091,456,618.